MOLECULAR DOCKING ANALYSIS OF THE BIOACTIVE COMPOUND EMODIN WITH VEGFR2 IN CERVICAL CANCER
Main Article Content
Keywords:
Molecular docking, Emodin, VEGFR2Abstract
Cervical cancer remains a leading cause of cancer-related mortality among women and represents the third most common cancer globally. Elevated VEGF expression in cervical cancer is associated with poor prognosis, highlighting the relevance of anti-VEGF therapeutic strategies. Several studies have shown that emodin, a natural anthraquinone derivative mainly isolated from Rheum palmatum, inhibits VEGF-stimulated proliferation, migration, and formation of endothelial cells. This study aims to characterize the interaction between emodin and the VEGF receptor in cervical cancer through in silico molecular docking. The workflow included preparation of the compound structure, preparation of the target protein structure, docking protocol validation, and docking of the compound to the receptor. Lower binding energy reflects a stronger and more stable interaction. The docking analysis showed that the emodin–VEGFR2 complex exhibits a binding energy of −7.78 kcal/mol, forming three hydrogen bonds with GLU915, CYS917, and LEU838, as well as three van der Waals interactions with PHE916, GLY920, and VAL846. These findings demonstrate a stable interaction between emodin and VEGFR2 and suggest its potential as a lead compound for further development of VEGFR2-targeted inhibitors, underscoring the need for subsequent in vitro and in vivo validation.
Article Details
References
1. World Health Organization (WHO). Cervical cancer [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
2. Fowler JR ME V, Dunton CJ, Gasalberti DP, Jack BW. Cervical Cancer. StatPearls [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30795952
3. Ferlay J, Ervik M, LamF. Global Cancer Observatory: Cancer Today [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today
4. Jumardi J, Arfah RA, Carrageenan PNU. Future Potential Ingredient of Lubricant and Feminine Hygiene Product with Possible Protection Effects against HPV Infection. Kem u Ind [Internet]. Available from: http://silverstripe.fkit.hr/kui/issue-archive/article/958
5. Kazazi-Hyseni F, Beijnen JH, Bevacizumab SJHM. Oncologist [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20688807
6. Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int J Mol Sci [Internet [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29670046
7. Zhang J, Liu J, Zhu C, He J, Chen J, Liang Y. Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis. Apr [Internet]. 11;8(15):24797–803. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28177889
8. Nair HH, V. A V, Anto RJ. Significance of nutraceuticals in cancer therapy. In: Evolutionary Diversity as a Source for Anticancer Molecules [Internet]. Elsevier. p. 309–21. Available from: https://linkinghub.elsevier.com/retrieve/pii/B978012821710800014X
9. Kwak H, Park M, Park C, Moon S, Yoo D, Lee H. Emodin inhibits vascular endothelial growth factor‐A‐induced angiogenesis by blocking receptor‐2 (KDR/Flk‐1) phosphorylation. Int J [Internet]. 14;118(11):2711–20. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ijc.21641
10. Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management [Internet]. 17;13(1):13398. Available from: https://www.nature.com/articles/s41598-023-40160-2
11. Sorkun MC, Khetan A, Er S. AqSolDB, a curated reference set of aqueous solubility and 2D descriptors for a diverse set of compounds [Internet]. 8;6(1):143. Available from: https://www.nature.com/articles/s41597-019-0151-1
12. Systèmes D. BIOVIA Discovery Studio Visualizer. San Diego: Dassault Systèmes.
13. ChemAxon. MarvinView. Budapest: ChemAxon.
14. Scripps Research Institute. AutoDockTools. La Jolla: CA: The Scripps Research Institute.
15. Fitriany J, Saputri AI. Anemia Defisiensi Besi. Jurnal Kesehat Masy. 4(1202005126):1–30.
16. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol [Internet]. Dec;1(4):337–41. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1740674904000551
17. Ahmad W, Ansari MA, Alsayari A, Almaghaslah D, Wahab S, Alomary MN. In Vitro, Molecular Docking and In Silico ADME/Tox Studies of Emodin and Chrysophanol against Human Colorectal and Cervical Carcinoma. Pharmaceuticals (Basel [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36355520
18. Halfdanarson TR, Jatoi A. Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep. 2010 Jul;12(4):247–52. doi:10.1007/s11912-010-0103-6 PubMed PMID: 20437116.
19. Shityakov S, Förster C. In silico predictive model to determine vector-mediated transport properties for the blood-brain barrier choline transporter. Adv Appl Bioinform Chem [Internet [Internet]. 7:23–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25214795
20. WF A, editor. Docking Screens for Drug Discovery [Internet]. New York, NY: Springer New York. Available from: http://link.springer.com/10.1007/978-1-4939-9752-7
21. Pourhajibagher M, Bahador A. Molecular Docking Study of Potential Antimicrobial Photodynamic Therapy as a Potent Inhibitor of SARS-CoV-2 Main Protease: An In silico Insight. Infect Disord - Drug Targets [Internet]. Available from: https://www.eurekaselect.com/208438/article
22. Cai X, Wang Z, Li X, Zhang J, Ren Z, Shao Y. Emodin as an Inhibitor of PRV Infection In Vitro and In Vivo [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37764342
23. Miyazaki Y, Matsunaga S, Tang J, Maeda Y, Nakano M, Philippe RJ. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett [Internet [Internet]. May;15(9):2203–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960894X05003409
24. U.S. Food and Drug Administration. New Drug Application (NDA): 021923.
25. Sangande F, Julianti E, Tjahjono DH. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2. Int J Mol Sci [Internet [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33096664
26. BCACD M. DRUG NAME : Axitinib.
27. Huey R, Morris GM. Using AutoDock 4 with AutoDockTools : A Tutorial. Vols. 1–56.
28. Ramírez D, Caballero J. Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data? Molecules. Apr [Internet]. 28;23(5):1038. Available from: https://www.mdpi.com
Article Sidebar
Download this PDF file
pdfPublished:
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.